These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
120 related items for PubMed ID: 29149550
1. A promising on-demand treatment option for bleeding events in haemophilia patients with inhibitors. Shapiro AD. Haemophilia; 2017 Nov; 23(6):810-811. PubMed ID: 29149550 [No Abstract] [Full Text] [Related]
2. The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors. Meeks SL, Leissinger CA. Haemophilia; 2019 Nov; 25(6):911-918. PubMed ID: 31489759 [Abstract] [Full Text] [Related]
3. NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds. Rice KM, Savidge GF. Haemostasis; 1996 Nov; 26 Suppl 1():131-4. PubMed ID: 8904187 [Abstract] [Full Text] [Related]
4. Experience of recombinant activated factor VII usage during surgery in patients with haemophilia with inhibitors. Polyanskaya T, Zorenko V, Karpov E, Sampiev M, Mishin G, Vasiliev D. Haemophilia; 2012 Nov; 18(6):997-1002. PubMed ID: 22672066 [Abstract] [Full Text] [Related]
5. Recombinant factor VIIa in joint and muscle bleeding episodes. Bech RM. Haemostasis; 1996 Nov; 26 Suppl 1():135-8. PubMed ID: 8904188 [Abstract] [Full Text] [Related]
6. Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry. Chambost H, Santagostino E, Laffan M, Kavakli K, ONE Registry Steering Committee on behalf of the investigators. Haemophilia; 2013 Jul; 19(4):571-7. PubMed ID: 23557542 [Abstract] [Full Text] [Related]
7. [Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia]. Levi M, Friederich PW, van der Meer J. Ned Tijdschr Geneeskd; 2002 Dec 28; 146(52):2534-7. PubMed ID: 12532665 [Abstract] [Full Text] [Related]
8. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Thromb Haemost; 1998 Dec 28; 80(6):912-8. PubMed ID: 9869160 [Abstract] [Full Text] [Related]
10. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding. Wang M, Lawrence JB, Quon DV, Ducore J, Simpson ML, Boggio LN, Mitchell IS, Yuan G, Alexander WA, Schved JF. Haemophilia; 2017 Nov 28; 23(6):832-843. PubMed ID: 28776894 [Abstract] [Full Text] [Related]
11. Cost effectiveness of prophylactic treatment with activated prothrombin complex concentrate in a patient with inhibitor-positive hemophilia A. Nakamura S, Morimoto A, Oh Y, Hayase T, Kashii Y, Gunji Y, Momoi MY. Blood Coagul Fibrinolysis; 2012 Apr 28; 23(3):235-7. PubMed ID: 22322137 [Abstract] [Full Text] [Related]
13. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors. Majumdar G, Savidge GF. Blood Coagul Fibrinolysis; 1993 Dec 28; 4(6):1031-3. PubMed ID: 8148476 [Abstract] [Full Text] [Related]